FDG PET评估T细胞淋巴瘤骨髓状态
研究回顾性纳入109例PTCL或NKTCL患者,以骨髓活检为金标准评估FDG PET诊断骨髓受累的效能及预后价值。PET视觉分析和MLR诊断敏感度分别为61.5%和64.1%,特异度分别为75.7%和72.9%。MLR是PFS和OS的独立预后因素,在骨髓活检阴性患者中亦有预后意义。
要点
- PET诊断骨髓受累敏感度61.5%(视觉)和64.1%(MLR),特异度75.7%和72.9%。
- MLR是PFS和OS的独立预后因素,在骨髓活检阴性患者中亦有预后意义。
- PET与骨髓活检一致性尚可,但可能无法替代骨髓活检。
核心结论
- PET与骨髓活检结果一致性尚可,但可能无法替代PTCL和NKTCL患者的骨髓活检。
- PET骨髓表现是独立预后因素,提示其额外生物学意义。
研究设计与样本
- 回顾性纳入109例PTCL或NKTCL患者(63例PTCL,46例NKTCL),均接受初始分期FDG PET和骨髓活检。
- PET骨髓表现采用视觉分析和骨髓-肝脏比值(MLR)定量评估,以骨髓活检为金标准评估诊断效能,并分析PFS和OS预后价值。
主要发现
- 骨髓活检显示35.8%病例存在骨髓受累。
- PET诊断阳性骨髓活检的敏感度和特异度:视觉分析为61.5%和75.7%,MLR为64.1%和72.9%。
- PET诊断效能在不同淋巴瘤类型间无差异。
- 生存分析显示MLR和骨髓活检结果对PFS和OS均有显著意义。
- 多因素分析中MLR是PFS和OS的独立预后因素,且在骨髓活检阴性患者中MLR亦是显著预后因素。
关键数值与推荐
- 视觉分析诊断骨髓受累敏感度61.5%、特异度75.7%。
- MLR诊断骨髓受累敏感度64.1%、特异度72.9%。
- 骨髓活检骨髓受累率35.8%。
临床怎么用
- FDG PET骨髓表现(MLR)可作为PTCL和NKTCL的独立预后因素参考。
- PET与骨髓活检一致性尚可,但可能无法替代骨髓活检。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In T-cell lymphoma, the role of FDG PET for bone marrow (BM) evaluation is not established yet. We investigated diagnostic performance and prognostic implication of FDG PET for BM evaluation in peripheral T-cell lymphoma (PTCL) and extranodal NK/T-cell lymphoma (NKTCL). PATIENTS AND METHODS: Patients with PTCL or NKTCL, who underwent initial staging with FDG PET and BM biopsy, were retrospectively enrolled and analyzed. PET BM finding was evaluated using visual analysis and a quantitative index (marrow-to-liver ratio [MLR]). Diagnostic performance of PET for BM involvement was assessed with biopsy as the gold standard. Prognostic value of PET findings was also assessed regarding progression-free survival (PFS) and overall survival (OS). RESULTS: A total of 109 (63 PTCL and 46 NKTCL) patients were analyzed. Biopsy revealed BM involvement in 35.8% of cases. Sensitivity and specificity of PET for diagnosing positive BM biopsy were 61.5% and 75.7% by visual analysis and 64.1% and 72.9% by MLR. Diagnostic performance of PET was not different across lymphoma types. Survival analysis revealed that MLR and BM biopsy result is significant for both PFS and OS. In multivariate analysis, MLR was an independent prognostic factor for both PFS and OS. Marrow-to-liver ratio was also a significant prognostic factor in BM biopsy-negative patients. CONCLUSIONS: Despite fair correlation with BM biopsy result, PET may not replace BM biopsy in PTCL and NKTCL. However, the BM finding on PET is an independent prognostic factor, suggesting additional biological implication of PET findings.
引用
- Koh Y, Lee JM, Woo GU, et al. FDG PET for Evaluation of Bone Marrow Status in T-Cell Lymphoma. Clin Nucl Med. 2019. PMID: 30371574. doi:10.1097/RLU.0000000000002320
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。